Navigation Links
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
Date:1/23/2012

SEATTLE, Jan. 23, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists for the treatment of cancer, today announced the publication of preclinical data demonstrating that VTX-2337, the Company's lead small molecule, is a novel, highly potent and selective TLR8 agonist. VTX-2337 directly activates human myeloid dendritic cells (mDCs), monocytes and natural killer (NK) cells resulting in the production of high levels of mediators known to orchestrate adaptive anti-tumor responses. Data were published in the journal Clinical Cancer Research.

(Logo: http://photos.prnewswire.com/prnh/20120123/SF39404LOGO)

The findings clearly distinguish TLR8 from other human TLRs. TLR8 is expressed on human monocytes, macrophages and mDCs circulating in blood and lymph nodes as well as on dendritic cells that are prevalent throughout the tumor microenvironment. Results demonstrate that the direct activation of mDCs by VTX-2337 results in a uniquely robust production of inflammatory cytokines and chemokines that increase cell mediated immunity and potentially enhance the anticancer effect of standard chemotherapy. Additionally, VTX-2337 has a direct effect on NK cells and augments antibody dependent cellular toxicity (ADCC), which supports the opportunity of combining VTX-2337 with monoclonal antibodies where ADCC contributes to clinical efficacy.

"These preclinical findings underscore the potential of a TLR8 agonist as a promising novel agent for cancer immunotherapy," said Mary L. Disis, M.D., professor of medicine in oncology at the University of Washington and associate dean of translational science at the UW School of Medicine, and co-author of the publication. "This research provides validation for current clinical trials evaluating VTX-2337 in combination with existing cancer treat
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Germany , July 30, 2014  invendo ... and computer-assisted ("robotic") colonoscopy system, today announced the appointment ... medical device executive, as a new member of its ... highly respected global visionary in the medical device industry. ... and Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... and Sanofi (EURONEXT: SAN and NYSE: SNY ... trials of alirocumab in people with hypercholesterolemia met their ... baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks ... investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type ...
(Date:7/30/2014)... , July 30, 2014  DigiPath, Inc. (OTCBB ... is expanding into the cannabis testing and education markets, ... its business and affairs not previously disclosed or, to ... recent unusual market action. "We have noticed ... the last three trading days," said Steve Barbee ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... Jan. 5, 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ... Phase 1 study with ISIS-TTRRx.  The results demonstrated ... reductions of greater than 80 percent in transthyretin ... well tolerated with no significant adverse events.  ISIS-TTRRx ...
... (NASDAQ: AMRI ), a global contract services ... preferred provider agreement with BioPontis Alliance LLC. The agreement ... gap between early-stage research and technologies being discovered and ... provide its services in small molecule discovery, development, and ...
Cached Medicine Technology:ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein 2ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein 3ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein 4AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC 2AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC 3
(Date:7/30/2014)... 30, 2014 Daily Gossip indicates in its ... easily. A panic attack is a feeling of intense stress ... are a series of symptoms that sufferers commonly deal with ... of breath, stress or anxiety. Naturally, panic attacks deeply affect ... way to overcome them. , The 60 Second Panic Solution ...
(Date:7/30/2014)... The Restore My Blood Sugar review recently ... sugar levels can now find an amazingly successful method of ... was created by D. Chao and Andrew Forester who claim ... when it comes to normalizing blood sugar levels. Chao actually ... secret to the cure of diabetes that all patients should ...
(Date:7/30/2014)... 30, 2014 Within weeks freshman will begin to ... Each hopes this will be a time of growth and the ... to pause; it may not be as easy as it looks. ... will switch their major at least once and many will switch ... and the costs are exacerbated when switching in the later years ...
(Date:7/30/2014)... July 30, 2014 Ticket Down ... Bayern Munich vs. Chivas Guadalajara friendly exhibition match at ... World Cup, the one team that was left standing as ... made it through the world’s largest football competition and even ... their way to the cup. Germany was led by seven ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July 30, 2014 ... to develop dementia, but researchers have been unable to explain ... Specifically, they haven,t been able to figure out the direction ... on dementia, or does dementia cause people to become depressed? ... journal Neurology sheds more light on the mystery. ...
Breaking Medicine News(10 mins):Health News:60 Second Panic Solution Review Reveals Unique Way to Stop Panic Attacks 2Health News:Restore My Blood Sugar Review Reveals Exclusive Ways to Normalize Blood Sugar 2Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3
... 16 A grassroots,effort to promote advance care planning ... than 450 participating organizations in,all 50 states. The first ... a year ago and implemented with no budget or,full-time ... am blown away by the response to our grassroots ...
... know anyone,who,s a Type-A personality? A multi-tasking, go-getter? ... would turn out to be Type-A.,There,s a lot ... But the antioxidants,deserve some special attention., (Photo: ... food by their deep-colored pigment - such as ...
... thinking skills, study finds , , WEDNESDAY, April 16 (HealthDay News) ... than women to develop mild cognitive impairment, new research shows. ... found more women than men [or an equal proportion] have ... men," study author Rosebud Roberts, of the Mayo Clinic in ...
... Abstract 19, Study highlights:, -- Low ... prevalence,of peripheral arterial disease (PAD) in a study that ... feel this needs further study and do not recommend,people ... by,their doctors., -- The American Heart Association recommends ...
... patient care while ... saving Medicaid dollars, ... Best Practices in Consumer Empowerment and,Protection Awards competition, naming the ... Eli Lilly,and Company as Silver Award winners in the Health ...
... Challenges Facing the ... Healthcare Industry, ... association with U.S. News & World Report,hosted an exclusive panel ... the National Press Club in Washington, D.C.,The event, attended by ...
Cached Medicine News:Health News:More Than 350 Events Today in Recognition of First National Healthcare Decisions Day 2Health News:Cranberries: The Little Fruit With a Great Big Punch 2Health News:Cranberries: The Little Fruit With a Great Big Punch 3Health News:Low Vitamin D Levels Associated With an Increased Risk of Peripheral Arterial Disease 2Health News:Low Vitamin D Levels Associated With an Increased Risk of Peripheral Arterial Disease 3Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 3Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 4Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 3
... Lubri-Flex Open Tip Ureteral Stents combine ... body temperature while remembering its shape with ... ultra-slippery when moistened. The result is a ... of placement and patient comfort. Lubri-Flex® is ...
... The Pathfinder Chlamydia Culture ... reliable staining of intracellular ... reticulate bodies) in tissue ... antibody used in this ...
... Pathfinder RSV EIA Kit is a direct antigen ... aspirates. It uses polyclonal and monoclonal antibodies ... This assay combines the specificity and reproducibility of ... an EIA. Qualitative results are availalbe within ...
The autoclavable, aluminum needle box is designed to store loaded needles and help protect personnel from exposure. Each shield consists of an aluminum box with faceplate to match the grid pattern th...
Medicine Products: